The survival study revealed that decreased HGB levels (< 110 g/L), FLT3-ITD mutations, and RUNX1 mutations had a negative influence on the OS of ASXL1+ AML patients (P = 0.045, P = 0.047, and P = 0.027, respectively; Additional file 3E, F). The gene discussed is RUNX1; the disease is acute myeloid leukemia.